

References

I-11

1. Estemalik E, Tepper S, Preventative treatment in migraine and the new US guidelines. *Neuropsychiatric Dis Treat*. 2013;(9):709-720.
2. Rothrock J, Bloudek L, Houle T, et al. Real world economic impact of onabotulinumtoxinA in patients with chronic migraine. The University of Alabama School Medicine, Allergan INC, Wake Forest University School of Medicine, et al.
3. Bumb A, Seifert B, Wetzel S, et al. Patients profiling for Botox®(onabotulinum toxin A) treatment for migraine a look at white matter lesions in the MRI as a potential marker. *Springerplus*. 2013;2:377.
4. Naumann M, Boo L, Ackerman A, et al. Immunogenicity of botulinum toxins. *J Neural Transm*. 2013;120(2):275-290.
5. Ramachandran R, Yaksh T. Therapeutic use of botulinum toxin in migraine: Mechanisms of action. *Br J Pharmacol*. 2014;171(18):4177-4192.
6. OH HM, Chung M. Botulinum toxin for neuropathic pain: A review of the literature. *Toxins (Basel)*. 2015;7(8):3127–3154.
7. Headache Classification Committee of the International Headache Society (IHS). The International Headache Society 3 rd edition (beta version);(ICHD-3 beta). *Cephalalgia*. 2013;33(9):629–808.
8. Lakraj A, Moghimi N, Jabbari B. Sialorrhea: Anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins. *Toxins(Base)*. 2013;5(5):1010-1031.
9. Persaud, R, Garas G, Silva S, et al. An evidence-based review of botulinum toxin (Botox) applications in non-cosmetic head and neck conditions. *J R Soc Med Sh Rep* 2013;4:10.
10. Srivanichapoom P, Pandey S, Hallett M. Drooling in Parkinson's disease: A review. Parkinson's disease (PD) is a neurodegenerative disease causing both motor and non-motor symptoms. *Parkinsonism Relat Disord*. 2014;20(11):1109–1118.
11. Strobl W, Theologis T, Brunner R, et al. Best clinical practice in botulinum toxin treatment for children with cerebral palsy. *Toxins*. 2015;7(5):1629-1648.
12. Elovic EP, Munin MC, Kanovsky P, et al: Randomized, placebo-controlled trial of incobotulinumtoxinA for upper-limb post-stroke spasticity. *Muscle Nerve*. 2016; 53(3):415-421.
13. Esquenazi A, Alfaro A, Ayyoub Z, et al. OnabotulinumtoxinA for lower limb spasticity: Guidance from a Delphi panel approach. *PM&R*. 2017; 1-9.
14. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. 2020. AbobotulinumtoxinA.
15. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. 2020. IncobotulinumtoxinA.
16. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. 2020. OnabotulinumtoxinA.

17. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. 2020. RimabotulinumtoxinB.
18. Aurora S, Dodick D, Diener H, et al., OnabotulinumtoxinA for Chronic Migraine: Efficacy, Safety, and Tolerability in Patients who Received All Five Treatment Cycles in the PREEMPT Clinical Program. *Acta Neurol Scand.* 2014;129:61-70.
19. Ranoux D, Martine G, Espagne-Debreuilh G, et al. OnabotulinumtoxinA Injections in Chronic Migraine, Targeted to Sites of Pericranial Myofascial Pain: an Observational, Open Label, Real-life Cohort Study. *J Headache Pain.* 2017;18:75-83.
20. Xeomin® (incobotulinumtoxinA) [package insert]. Merz Pharmaceuticals, LLC. Raleigh, NC. 05/2019.
21. Myobloc® (rimabotulinumtoxinB) [package insert]. Solstice Neurosciences, Inc. Louisville, KY. 08/2019.
22. Dysport® (abobotulinumtoxinA) [package insert]. Ipsen Biopharm, Ltd. Cambridge, MA. 09/2019.
23. Botox® (onabotulinumtoxinA) [package insert]. Allergan, Inc. Madison, NJ. 10/2019.
24. Micromedex DrugDex Compendium®. 2020. AbobotulinumtoxinA.
25. AbobotulinumtoxinA In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated 2020.
26. AbobotulinumtoxinA. Lexi-Drugs. Hudson, OH: Lexicomp, 2020.
27. Micromedex DrugDex Compendium®. 2020. IncobotulinumtoxinA.
28. IncobotulinumtoxinA In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated 2020.
29. IncobotulinumtoxinA. Lexi-Drugs. Hudson, OH: Lexicomp, 2020.
30. Micromedex DrugDex Compendium®. 2020. OnabotulinumtoxinA.
31. OnabotulinumtoxinA In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated 2020.
32. OnabotulinumtoxinA. Lexi-Drugs. Hudson, OH: Lexicomp, 2020.
33. Micromedex DrugDex Compendium®. 2020. RimabotulinumtoxinB.
34. RimabotulinumtoxinB In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated 2020.
35. RimabotulinumtoxinB. Lexi-Drugs. Hudson, OH: Lexicomp, 2020.
36. Hayes, Inc. Hayes Health Technology Report. Botulinum Toxin Treatment of Gastroparesis. Lansdale, PA: Hayes, Inc.; March, 2020.

37. Hayes, Inc. Hayes Medical Technology Directory. Local Injection Therapy for Cervicogenic Headache and Occipital Neuralgia. Lansdale, PA: Hayes, Inc.; September, 2017.
38. Hayes, Inc. Hayes Health Technology Assessment. Botulinum Toxin Treatment for Migraine Headache. Lansdale, PA: Hayes, Inc.; August, 2019.
39. Hayes, Inc. Hayes Evidence Analysis Research Brief. Botulinum Toxin for Treatment of Raynaud's Syndrome. Lansdale, PA: Hayes, Inc.; January, 2020.
40. Hayes, Inc. Hayes Evidence Analysis Research Brief. Botulinum Toxin for Treatment of Pain Associated with Temporomandibular Disorders. Lansdale, PA: Hayes, Inc.; February, 2020.
41. Pellegrini M, Schiavi C, Taroni L, et al. Ocular surface status in patients with hemifacial spasm under long-lasting treatment with botulinum A toxin: A comparative fellow eye study. *Indian J Ophthalmol* 2019;67:1405-9.
42. Arai S, Fukase Y, Okii A, Suzukamo Y & Suga T. Selection process for botulinum toxin injections in patients with chronic-stage hemiplegic stroke: a qualitative study. *BMC Med Inform and Decis Mak*. 2019;19:280-291.
43. Yana M, Tutuola F, Westwater-Wood S, & Kavlak E. The efficacy of botulinum toxin A lower limb injections in addition to physiotherapy approaches in children with cerebral palsy: A systematic review. *Neurorehabil*. 2019;44:175-189.
44. Chen J & Kuo H. Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis. *Investig Clin Urol*. 2020;61 Suppl 1:S33-42.